BTIG raised the firm’s price target on Nektar (NKTR) to $151 from $118 and keeps a Buy rating on the shares. The stock remains one of the firm’s 1H26 Top Picks, and following the company’s latest update, the firm has updated its Rezpeg in atopic dermatitis market model tot reflect use as a first-line Tx options for advanced-Tx eligible patients. The firm added that it anticipated new/deepening responses to emerge as a significant differentiator for Rezpeg and sees this feature persuasively confirmed in 52-week REZOLVE-AD results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar upgraded to Outperform from Market Perform at William Blair
- William Blair upgrades Nektar on durability and deepening of rezpeg response
- Nektar price target raised to $165 from $135 at H.C. Wainwright
- Nektar Advances Rezpegaldesleukin After Positive Phase 2b Data
- Nektar management to meet virtually with Piper Sandler